65 related articles for article (PubMed ID: 7998906)
21. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2.
Guichard G; Connan F; Graff R; Ostankovitch M; Muller S; Guillet JG; Choppin J; Briand JP
J Med Chem; 1996 May; 39(10):2030-9. PubMed ID: 8642561
[TBL] [Abstract][Full Text] [Related]
22. Possible association of non-binding of HSP70 to HLA-DRB1 peptide sequences and protection from rheumatoid arthritis.
Maier JT; Haug M; Föll JL; Beck H; Kalbacher H; Rammensee HG; Dannecker GE
Immunogenetics; 2002 May; 54(2):67-73. PubMed ID: 12037598
[TBL] [Abstract][Full Text] [Related]
23. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
24. Peptide-MHC interaction: a rational approach to vaccine design.
Romagnoli P; Takacs B; Kilgus J; Pink JR; Sinigaglia F
Int Rev Immunol; 1990; 6(1):61-73. PubMed ID: 2151722
[No Abstract] [Full Text] [Related]
25. Interactions between immunogenic peptides and HLA-DR molecules.
Rothbard JB; Busch R
Immunol Res; 1990; 9(3):178-89. PubMed ID: 2230404
[No Abstract] [Full Text] [Related]
26. A Novel Peptide Binding Prediction Approach for HLA-DR Molecule Based on Sequence and Structural Information.
Li Z; Zhao Y; Pan G; Tang J; Guo F
Biomed Res Int; 2016; 2016():3832176. PubMed ID: 27340658
[TBL] [Abstract][Full Text] [Related]
27. A roadmap for HLA-DR peptide binding specificities.
Chelvanayagam G
Hum Immunol; 1997 Dec; 58(2):61-9. PubMed ID: 9475335
[TBL] [Abstract][Full Text] [Related]
28. Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice.
Menconi F; Monti MC; Greenberg DA; Oashi T; Osman R; Davies TF; Ban Y; Jacobson EM; Concepcion ES; Li CW; Tomer Y
Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14034-9. PubMed ID: 18779568
[TBL] [Abstract][Full Text] [Related]
29. Mutations to the alpha-2 domain of human class II molecules alters the efficiency of peptide loading and antigen presentation.
Lamikanra A; Grüneberg U; Altmann D; Travers P
Biochem Soc Trans; 1997 May; 25(2):357S. PubMed ID: 9191402
[No Abstract] [Full Text] [Related]
30. 'Peptoid' design.
Horwell DC; Howson W; Rees DC
Drug Des Discov; 1994 Jul; 12(1):63-75. PubMed ID: 7578808
[No Abstract] [Full Text] [Related]
31. The state of aggregation of MHC class II molecules at the cell-surface is temperature dependent.
Triantafilou K; Wilson KM; Morrison IE; Cherry RJ; Fernandez N
Biochem Soc Trans; 1997 May; 25(2):358S. PubMed ID: 9191403
[No Abstract] [Full Text] [Related]
32. Prediction of peptide affinity to HLA DRB1*0401.
Rothbard JB; Marshall K; Wilson KJ; Fugger L; Zaller D
Int Arch Allergy Immunol; 1994 Sep; 105(1):1-7. PubMed ID: 8086825
[TBL] [Abstract][Full Text] [Related]
33. HLA-DR: molecular insights and vaccine design.
Stern LJ; Calvo-Calle JM
Curr Pharm Des; 2009; 15(28):3249-61. PubMed ID: 19860674
[TBL] [Abstract][Full Text] [Related]
34. Experimental strategies to explore the molecular details of MHC-peptide complexes.
Rothbard JB; Busch R; Hill CM
Int Rev Immunol; 1990; 6(1):1-21. PubMed ID: 2102902
[No Abstract] [Full Text] [Related]
35. HLA association with autoimmune disease: restricted binding or T-cell selection?
Baum H; Wilson C; Tiwana H; Ahmadi K; Ebringer A
Lancet; 1995 Oct; 346(8981):1042-3. PubMed ID: 7475580
[No Abstract] [Full Text] [Related]
36. Comment on Dorak and Burnett.
Baum H; Cunningham P
Immunol Today; 1995 Feb; 16(2):107. PubMed ID: 7534084
[No Abstract] [Full Text] [Related]
37. Single particle imaging of cell-surface HLA-DR tetramers.
Wilson KM; Triantafilou K; Morrison IE; Cherry RJ; Fernandez N
Biochem Soc Trans; 1997 May; 25(2):360S. PubMed ID: 9191405
[No Abstract] [Full Text] [Related]
38. New ways of making drugs. RNA and peptides by selection and molecular design.
Cassani G
Ann N Y Acad Sci; 1993 Dec; 700():36-42. PubMed ID: 7509139
[No Abstract] [Full Text] [Related]
39. Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.
Venturini S; Mosier DE; Burton DR; Poignard P
J Virol; 2002 Jul; 76(14):6987-99. PubMed ID: 12072499
[TBL] [Abstract][Full Text] [Related]
40. Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.
Kitze B; Usuku K; Yamano Y; Yashiki S; Nakamura M; Fujiyoshi T; Izumo S; Osame M; Sonoda S
Clin Exp Immunol; 1998 Feb; 111(2):278-85. PubMed ID: 9486393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
